Effect of management strategies and clinical status on costs of care for advanced HIV

American Journal of Managed Care

Volumn 20, Issue 5, 2014, Pages

  Barnett, Paul G ^a   Chow, Adam ^a   Joyce, Vilija R ^a   Bayoumi, Ahmed M ^b,c   Griffin, Susan C ^d   Sun, Huiying ⁱ   Holodniy, Mark ^a   Brown, Sheldon T ^f   Cameron, D William ^g   Sculpher, Mark ^d   Youle, Mike ^h   Anis, Aslam H ^i,j   Owens, Douglas K ^a,e  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e STANFORD UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF OTTAWA   (Canada)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ Canadian HIV Trials Network   (Canada)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; OPPORTUNISTIC INFECTION; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED KINGDOM; UNITED STATES; VIRUS LOAD; COMPLICATION; CONTROLLED STUDY; ECONOMICS; HEALTH STATUS; HIV INFECTIONS; HOSPITALIZATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH STATUS; HEPATITIS C; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 84903640154     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Beck EJ, Harling G, Gerbase S, DeLay P. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008. Curr Opin HIV AIDS. 2010;5(3):215-224.
2. Hellinger FJ, Encinosa WE. Antiretroviral therapy and healthcare utilization: a study of privately insured men and women with HIV disease. Health Serv Res. 2004;39(4, pt 1):949-967. treatment: why it is more than ever needed? Curr Opin HIV AIDS. 2010;5(3):201-203.
3. Moatti JP, Eboko F. Economic research on HIV prevention, care and treatment: why it is more than ever needed? Curr Opin HIV AIDS. 2010;5(3):201-203.
4. Harris M, Nosyk B, Harrigan R, Lima VD, Cohen C, Montaner J. Costeffectiveness of antiretroviral therapy for multidrug-resistant HIV: past, present, and future. AIDS Res Treat. 2012;2012:595762.
5. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012;26(1):45-56.
6. Hubben GA, Bos JM, Veltman-Starkenburg CA, et al. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc. 2007;5:15.
7. Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012;26(3):355-364.
8. Kuhne FC, Chancellor J, Mollon P, Myers DE, Louie M, Powderly WG. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIVinfected individuals. HIV Clin Trials. 2010;11(2):80-99.
9. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med. 2013;158(2):84-92.
10. Hellinger FJ. Economic models of antiretroviral therapy: searching for the optimal strategy. Pharmacoeconomics. 2006;24(7):631-642. (Pubitemid 43998816)
11. Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344(11):817-823. (Pubitemid 32222161)
12. Chen RY, Accortt NA, Westfall AO, et al. Distribution of healthcare expenditures for HIV-infected patients. Clin Infect Dis. 2006;42(7): 1003-1010.
13. Moore RD, Chaisson RE. Costs to Medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(3):223-231.
14. HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002;30(1):21-26.
15. Beck EJ, Tolley K, Power A, et al. The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs. Pharmacoeconomics. 1998;14(6):639-652.
16. Yazdanpanah Y, Goldie SJ, Losina E, et al. Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2002;7(4):257-266. (Pubitemid 36427130)
17. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6(3):171-177. (Pubitemid 43267642)
18. Farnham PG. Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment? Appl Health Econ Health Policy. 2010;8(2):75-88.
19. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45(12):1593-1601. (Pubitemid 351411845)
20. Barnett PG, Chow A, Joyce VR, et al. Determinants of the cost of health services used by veterans with HIV. Med Care. 2011;49(9):848-856.
21. Roberts RR, Kampe LM, Hammerman M, et al. The cost of care for patients with HIV from the provider economic perspective. AIDS Patient Care STDS. 2006;20(12):876-886. (Pubitemid 46106074)
22. Rothbard AB, Metraux S, Blank MB. Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. Psychiatr Serv. 2003;54(9):1240-1246. (Pubitemid 37055985)
23. Purdum AG, Johnson KA, Globe DR. Comparing total healthcare costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 2004;16(6):767-780. (Pubitemid 39158989)
24. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004;5(2):93-98. (Pubitemid 38404662)
25. Krentz HB, Gill J. Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl. AIDS. 2010;24(17): 2750-2753.
26. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24(17):2705-2715.
27. Holodniy M, Brown ST, Cameron DW, et al. Results of antiretroviral treatment interruption and intensification in advance multi-drug resistant HIV infection from the OPTIMA trial. PLoS ONE. 2011;6(3):10.
28. Kyriakides TC, Babiker A, Singer J, et al. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Control Clin Trials. 2003;24(4):481-500. (Pubitemid 36831050)
29. Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60(3):15S-36S. (Pubitemid 36993492)
30. Phibbs CS, Bhandari A, Yu W, Barnett PG. Estimating the costs of VA ambulatory care. Medical Care Research and Review. 2003;60(3): 54S-73S. (Pubitemid 36993495)
31. United States Congress Congressional Budget Office. Prices for brand-name drugs under selected federal programs. Washington, DC; 2005.
32. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20(4):461-494. (Pubitemid 32515166)
33. Box GEP, Cox DR. An analysis of transformations. J Royal Stat Soc Series B Stat Methodol. 1964;26(2):211-252.
34. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika. 2000;87(2):329-343.
35. Hoyle M. Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics. 2011;29(1):1-15.
36. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-997. (Pubitemid 44674030)